Kornimate/medical-research-clean huggingface dataset:
theta burst tms as a tool to change smoking behavior

Conditions: Smoking; Addiction

Summary: the goal of this study is to determine whether transcranial magnetic stimulation (tms) is an effective treatment in decreasing craving in individuals who habitually smoke cigarettes. the study consists of six total visits to musc; one for the consent process, two that will include mri scans, and five that will include tms administration. compensation will be provided for each visit.

prior and recent evidence suggests a role of medial prefrontal cortex (mpfc) in cigarette smoking. the present study will examine whether a five-day regimen of theta-burst transcranial magnetic stimulation (tms) reduces cigarette smoking outside of the lab (examined through self-report and physiological measures) and motivation to smoke inside the lab (examined through behavioral tasks and functional mri).

Eligibility criteria:
inclusion criteria: * smoke at least 10 cigarettes a day (on average) exclusion criteria: * comorbid mental or physical illness (managed or unmanaged) * pregnancy * use of prescription medication that might affect smoking or nicotine metabolism, * use of smokeless tobacco or alternative nicotine products * use illicit drugs of abuse (verified through urine screen and self-report), * score of above a 7 on the alcohol use disorders identification test (indicative of non-risky use), * a history of epilepsy or seizures not otherwise specified (other than childhood febrile seizures) * a history of chronic migraines, * failure to meet all criteria on a standardized mri/tms safety screen (including but not limited to implanted electronic devices, bullets or metallic fragments above the waist, hair clips and piercings above the waist that cannot be removed) * presence of any barriers to making contact between the tms coil and the skin (e.g. cornrows that cannot be removed, glasses that the participant is unwilling to remove).

Keywords: transcranial magnetic stimulation
flumatinib in cml-cp patients with ph+ post imatinib failure

Conditions: Flumatinib; Chronic Myeloid Leukemia, Chronic Phase; Imatinib

Summary: the purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (cml-cp) patients with ph+ post imatinib failure.

a multicenter, single-arm, prospective, open-label study to detect the efficacy and safety of flumatinib by measuring rates of major molecular response (mmr) at 12 months in cml-cp patients with ph+ in china. approximately 200 patients will be recruited consecutively from the study sites during the enrollment period and will be given flumatinib 600 mg qd. the duration of patient participation will be 24 months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * diagnosis of cml-cp with ph+. * ecog performance of 0-2. * adequate end organ function defined as the following: total bilirubin \<1.5x uln, sgpt \<2.5x uln, creatinine \<1.5x uln. * treatment failure after imatinib at 3 or 6 months with bcr-abl \>10%. * patients must sign an informed consent form (icf) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital. exclusion criteria: * previously documented t315i mutation. * history of tki treatments except of imatinib. * history of undergone major surgery within 4 weeks. * patients unwilling or unable to comply with the protocol. * pregnant or breast-feeding patients. * patients with other malignant tumor.

Keywords: flumatinib, cml-cp with ph+
sparkle respiratory effort validation

Conditions: Sleep Apnea, Obstructive; Sleep Apnea, Central

Summary: this study has been developed in order to demonstrate the validity of the sparkle respiratory effort signal.

the rationale for undertaking this study is to demonstrate that the agreement between the sparkle respiratory effort signal amplitude and esophageal manometry is non-inferior to the agreement between the thoracic belt respiratory effort signal amplitude and esophageal manometry. data collection will be completed within a single visit, in which participants will undergo simultaneous measurement using the sparkle device, respiratory belts, and esophageal manometry. data collection will be completed during wakefulness, while participants undergo a series of breathing maneuvers.

Eligibility criteria:
inclusion criteria: * aged ≥18 years; * fluent in english; * able to provide informed consent. exclusion criteria: * contraindication to esophageal pressure monitoring, including a sensitive gag reflex (determined by a positive response to the screening question "do you sometimes or often gag while brushing your teeth?"), dysphagia, nasal obstruction, and/or esophageal disorder likely to impact placement of the balloon; * history of allergic reactions to medical adhesives; * known allergy to lidocaine; * known seizure disorder; * severe medical condition (controlled or uncontrolled) impacting breathing including neuromuscular disease, chronic obstructive pulmonary disease, respiratory failure or insufficiency, or requirement for oxygen therapy; * chronic cardiopulmonary or renal disease, including a history of irregular heart rhythms; * at risk for excessive bleeding including use of anticoagulants; * an employee, or spouse of an employee, of a company that designs, sells, or manufactures sleep related products (including philips); * an employee, or spouse of an employee, of pulmonary and critical care associates of baltimore.
study to evaluate plasmin for the creation of a posterior vitreous detachment

Conditions: Vitreoretinal Traction Syndrome

Summary: plasmin is expected to create a posterior vitreous detachment. the pharmacological creation of a posterior vitreous detachment may be beneficial in a variety of conditions.


Eligibility criteria:
inclusion criteria: * patients who would benefit from a posterior vitreous detachment, as determined by the evaluating ophthalmologist. exclusion criteria: * presence of a posterior vitreous detachment in the study eye * history of vitrectomy in the study eye * proliferative diabetic retinopathy in the study eye * presence of media opacity that precludes quality examination of the vitreous and fundus.
evaluation of an app to alleviate stress among caregivers of people with dementia

Conditions: Caregiver Burden

Summary: caregivers of people living with dementia experience significant stress which can negatively affect their mental health. the goal of our study is to test a newly developed app that focuses on providing stress management strategies for caregivers of people living with dementia.

caregivers of people living with dementia experience significant stress which can negatively affect their mental health. psychological interventions that focus on building skills and providing strategies to improve their well-being have been shown to improve caregiver well-being. although mobile applications (apps) are available for caregivers of people living with dementia, existing apps do not adequately address the stress and mental health needs experienced by caregivers of people living with dementia. in addition, there is a paucity of mobile app interventions that provide practical stress management strategies for caregivers. the goal of the study is to conduct an evaluation of a novel app (ur caregiver) that focuses on providing stress management strategies for caregivers of people living with dementia. the app utilizes cognitive behavioural principles and is consistent with models of stress and coping. caregivers of people living with dementia will be recruited and randomly assigned to three groups: 1) ur caregiver; 2) active control; and 3) non-app using control. participants in the app-using groups will be asked to use the app over an 8-week period. stress, burden, and mental health will be assessed before, after the 8-week period, and at a follow-up period. a 3 between (group) by 3 within (time: baseline, post, follow-up) mixed model (repeated measures) multivariate analysis of variance and univariate analyses will be conducted to examine improvements on outcome measures over time. given the demands that caregivers of people living with dementia face daily, the creation and evaluation of an app that aims to provide stress-management strategies has the potential of improving the quality of life of caregivers of people living with dementia.

Eligibility criteria:
inclusion criteria: 1. caregivers providing informal and unpaid care (e.g., spouses, children, relatives) for a person living with dementia 2. providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia 3. own a smartphone/tablet (i.e., can access either ios or android platforms). exclusion criteria: 1) currently using an app for caregiver stress/burden

Keywords: dementia mobile app
low and high doses of prophylactic vitamin d in prevention of osteopenia of prematurity

Conditions: Osteopenia of Prematurity

Summary: in this study the effects of low and high doses of prophylactic vitamin d on biochemical and radiological manifestations of osetopenia of prematurity will be tested.

the study will be conducted on (80) preterm infants that fulfill the eligibility criteria and delivered at alexandria university maternity hospital (aumh).

Eligibility criteria:
inclusion criteria: * newborns with gestational age of ≤ 32 weeks and birth weight ≤ 1500 g. exclusion criteria: * newborns whose mothers were taking specific medications interacting with vitamin d metabolism (e.g., anticonvulsants, diuretics) * being npo (nothing per oral) for more than 2 wks * gestational age more than 32 weeks * birth weight more than 1500 grams
a study to evaluate the efficacy and safety of syhx1901 tablet in non-segmental vitiligo patients

Conditions: Non-segmental Vitiligo

Summary: a 52-week study of syhx1901 tablet in adults with non-segmental vitiligo.

syhx1901 tablet is being evaluated for the treatment of non-segmental vitiligo. the study will enroll approximately 144 participants aged 18-65 with non-segmental vitiligo in 4 treatment arms. participants will either receive study drug vs placebo oral tablets once daily (qd) for 24 weeks (period a). in period b (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. participants who received study drug during the first 24 weeks, will continue to receive study drug.

Eligibility criteria:
inclusion criteria: 1. willing to sign an icf, able to comprehend and comply with the study procedures. 2. male or female subjects aged 18 to 65，inclusive. 3. subjects with a clinical diagnosis of non-segmental vitiligo. 4. agree to stop all other treatments for vitiligo during the study period. 5. women of child-bearing potential must have a negative serum pregnancy test within 3 days prior to the first study agent administration. exclusion criteria: 1. diagnosed as other active depigmentation disease. 2. at screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment. 3. uncontrolled thyroid function at screening as determined by the investigator. 4. use of permanent depigmentation treatment or skin grafts. 5. use of phototherapy, topical or systemic treatments within certain time frame prior to day1. 6. have active bacterial/virus/other pathogens infection or infestation that require medical intervention. 7. have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study. 8. history of alcohol and drug abuse within one year prior to screening; history of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc. 9. have any other reasons determined by the investigator that the subject is not eligible for the study.
chronic obstructive pulmonary disease gene localization

Conditions: Lung Diseases; Chronic Obstructive Pulmonary Disease

Summary: to localize within the genome a chronic obstructive pulmonary disease susceptibility gene.

background: chronic obstructive pulmonary disease (copd) is a slowly progressive disorder characterized by airways obstruction that lasts for at least several months. the two major causes of copd are chronic bronchitis and emphysema. either disorder may occur with or without airways obstruction, but airways obstruction causes impairment of lung function leading to disability and death. copd is a major health problem in the united states and throughout the world, consistently ranking among the most common causes of death in the united states. cigarette smoking is the primary environmental factor that increases the risk of copd, but other environmental factors have also been implicated. however, despite a well-established role, environmental factors alone do not cause copd. symptomatic copd develops in only 10-20 percent of heavy cigarette smokers, probably those with a genetic susceptibility, although common copd susceptibility genes have yet to be identified. design narrative: the study applied statistical linkage analysis to family data. pulmonary measurements had already been collected on 159 members of 16 pedigrees and evidence supporting a copd susceptibility gene in these pedigrees had been obtained from segregation analysis. each of 11,995 genetic markers, which had already been genotyped on pedigree members, were tested for evidence of linkage to the inferred copd susceptibility gene. evidence of linkage to one or more genetic markers identifed genomic locations of copd susceptibility genes. the high density of markers allowed fine-mapping of the gene. successful completion of this gene localization project was the necessary prerequisite for a project to identify and characterize a copd susceptibility gene. identifying a gene that when mutated increased the risk of copd may increase understanding of pulmonary function, as well as allowing gene-carriers to be identified and made aware of their susceptibility.

Eligibility criteria:
no eligibility criteria
hemoadsorption with cytosorb® in post-cardiac arrest syndrome

Conditions: Cardiac Arrest

Summary: this prospective single-centre randomized control trial aims at evaluating the safety and efficacy of hemoadsorption with cytosorb® in 40 patients with post-cardiac arrest syndrome admitted to the icu.

patients presenting post-cardiac arrest syndrome (pcas) in the 24 hours following their admission in intensive care unit will be randomly assigned either to a control group (standard of care) either to a "hemoadsorption" group. in the latter, the patient will be connected in the 6 hours following randomization to an extracorporeal circuit, in which a cytosorb ® cartridge will be placed. the circuit will be set up in hemoperfusion mode. the therapy will take place for a minimum of 12 hours and a maximum of 24 hours. anticoagulation will be achieved using a regional heparin-protamin regimen. blood samples will be collected at randomization, t1 (6 hours post-randomization), t2 (12 hours after randomization), t3 (24 hours after randomization), t4 (48 hours after randomization) and t5 (48 hours after randomization), to assess change in inflammatory cytokine levels.

Eligibility criteria:
adult (≥18 years old) patients admitted to the icu after ca, at risk of pacs as defined by the presence of at least one of the following characteristics (at any time within 24hrs of ca): * need for a vasoconstrictor (norepinephrine dose \> 0.2 µg/kg/min to maintain map \> 60-70 mmhg, , or equivalent vasoconstrictor agent) for at least one hour * serum lactate level \> 6 mmol/l * time to rosc \> 25 minutes exclusion criteria: * evidence for patient's refusal to participate in clinical trials * non commitment for ongoing medical therapy (imminent withdrawal of care) * cardiac arrest caused by hemorrhagic shock * contraindications to therapeutic heparinization * shock of primary cardiac origin (lvef \<20%) * platelet count \<20 g/l * deep immunosuppression state, as defined by neutrophils \<1 g/l or cd4 \<200 /mm3 * pregnancy * acute sickle cell crisis * refractory cardiac arrest with ecmo implantation * need for renal replacement therapy at time of randomization * concomitant enrolment in another study * non availability of the research team at time of eligibility at time of randomization

Keywords: cardiac arrest cytokine hemoadsorption
a study to evaluate the effect of lcz696 on aortic stiffness in subjects with hypertension

Conditions: Hypertension

Summary: this was the first evaluation of the effects of lcz696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. the results of this exploratory study will help to understand the mechanism of action of lcz696 and used to inform the design of future clinical studies with lcz696 in subjects with cardiovascular diseases.


Eligibility criteria:
key inclusion criteria: * subjects with essential hypertension, untreated or currently taking antihypertensive therapy key exclusion criteria: * women of child bearing potential (wocbp) if not on highly effective contraception * malignant or severe hypertension (grade 3 of who classification) * history or evidence of a secondary form of hypertension * transient ischemic cerebral attack (tia) during the 12 months prior to screening or any history of stroke. * previous or current diagnosis of heart failure (new york heart association class ii-iv).

Keywords: lcz696, hypertension, aortic stiffness, central blood pressure, cardiovascular mri
home-based cycling for people with lumbar spinal stenosis

Conditions: Symptomatic Lumbar Spinal Stenosis

Summary: the main objective of the study is to compare the efficacy on back-specific activity limitations at 4 months after-randomisation of home-based cycling using connected ergometric bicycles associated with usual care to usual care.

lumbar spinal stenosis is a prevalent and disabling condition in elderly people. lumbar spinal stenosis results in back and leg pain when standing and walking (radicular claudication), while symptoms regress in sitting position. the inability to stand or walk significantly impairs functioning and health-related quality of life of elders, and has an important healthcare cost. the 2 main treatment options for lumbar spinal stenosis are conservative or surgical treatments. previous data suggested that laminectomy may be more effective on pain and function than conservative therapy. however, the benefit-risk balance of surgery should be carefully considered in this population with numerous co-morbidities, and evidence is inconsistent. therefore, conservative therapy is usually the first line option. data regarding exercise therapy are scarce. flexion-based exercises are usually recommended. a pilot study suggested that flexion-based endurance training program, namely cycling, could be an effective and safe method to improve pain, function and health-related quality of life in elderly people with chronic lumbar pain. however, barriers to adhering to the program were detected and might have influenced clinical endpoints. non-pharmacological interventions in spinal conditions are not 'one-size-fits-all' and measures to enhance adherence have to be applied. the hypothesis is that home-based cycling using connected ergometric bicycles associated with usual care could be more effective than usual care in reducing back-specific activity limitations at 4 months in people with lumbar spinal stenosis.

Eligibility criteria:
inclusion criteria: * age ≥ 50 year-old * radicular claudication (i.e. walking-induced low back, buttock and/or leg pain, relieved in siting and/or lumbar flexion positions) diagnosed by a physician * mri or ct-scan findings consistent with lss reported on a written radiology report provided by a board-certified radiologist or a resident in radiology exclusion criteria: * inability to speak and/or read french language * inability or refusal to perform ergometric bicycle at home * patients already having an ergometric bicycle at home * history of lumbar spine surgery in the previous 12 months * cognitive disorders * severe neurologic or vascular disorders involving the lower limbs * contraindication to a rehabilitation program assessed by medical examination * people under tutorship or curatorship * protected adults

Keywords: lumbar spinal stenosis neurogenic claudication low back pain exercise therapy endurance training cycling randomized trial
a study to assess programmed death ligand-1 (pd-l1) expression in cytological versus histological lung cancer specimens

Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell

Summary: the primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing pd-l1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (nsclc) or small cell lung cancer (sclc).


Eligibility criteria:
inclusion criteria: * samples must have been collected in a manner that is compliant with local ethics committee guidance * samples must originate from participants diagnosed with nsclc or sclc * participants must have a pair of at least one cytological and one histological specimen that: both originate from inside the thorax or from the same ex-thoracic site; are confirmed to have been collected within a window no more than 6 weeks apart from each other; and are in compliance with the protocol defined sample requirements for histological and cytological specimens exclusion criteria: * immune checkpoint inhibitor therapy from 4 weeks prior to collection of the first tumor sample until collection of the second matched sample